*The recommended maintenance dose of aspirin to be used with ticagrelor is 81 mg daily.290 aPTT indicates activated partial thromboplastin time; BID, twice daily; COR, Class of Recommendation; CrCl, creatinine clearance; DAPT, dual antiplatelet therapy; GP, glycoprotein; IV, intravenous; LOE, Level of Evidence; max, maximum; N/A, not available; NSTE-ACS, non-ST-elevation acute coronary syndromes; PCI, percutaneous coronary intervention; SC, subcutaneous; and UFH, unfractionated heparin. in patients with stable ischemic heart disease.291 When pos- sible, discontinue clopidogrel at least 5 days before surgery.301 Prasugrel The metabolic conversion pathways of prasugrel produce more rapid and consistent platelet inhibition than clopido- In patients with NSTE-ACS and defined coronary anatomy undergoing planned PCI, a 60-mg loading dose of prasugrel followed by 10 mg daily was compared with a 300-mg loading dose and 75 mg daily of clopidogrel. The composite primary endpoint (cardiovascular death, nonfatal MI, and stroke) was reduced in patients treated with prasu- grel (hazard ratio [HR]: 0.81; P=0.001). This was driven by a risk reduction for MI and stent thrombosis with no differ- ence in mortality.302 Counterbalancing the salutary effects of prasugrel was a significant increase in spontaneous bleeding, life-threatening bleeding, and fatal bleeding in the patients treated with prasugrel compared with patients treated with clopidogrel. 